Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17747 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Viviane Liao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Janus Kinase Inhibitors, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The JAK/STAT pathway is implicated in the pathogenesis of cutaneous T‐cell lymphoma (CTCL), with early studies suggesting that JAK inhibitors (JAKi) may be used for treating CTCL. Patients with CTCL may have other indications for JAKi use, but data on JAKi agents in CTCL is limited due to warnings against their use in malignancy. We retrospectively characterized the experience of our tertiary cancer center with JAKi in patients seen for CTCL between the years 2011 and 2024. We identified 26 CTCL patients who received a JAKi: 7 received a JAKi prior to their CTCL diagnosis (topical ( n = 5) or oral ( n = 2) for itchy rash or eczema), 6 received a JAKi as CTCL treatment, and 13 received a JAKi for other indications following a diagnosis of CTCL (oral ruxolitinib for graft versus host disease (GvHD) following allogeneic stem cell transplant ( n = 9), oral ruxolitinib for hemophagocytic lymphohistiocytosis ( n = 3), or topical ruxolitinib for alopecia areata ( n = 1)). Of the six patients treated for CTCL with a JAKi, four received oral ruxolitinib and two received topical ruxolitinib. One patient treated orally has had a complete response for 3 years and another patient has had a diminishing lesion size for 1 year. One patient treated topically for skin‐limited CTCL demonstrated plaque thinning. Of the nine patients treated for GvHD, five experienced CTCL relapse a median of 8 weeks following ruxolitinib exposure. This study provides initial insights into the real‐world use of JAKi in patients with CTCL. Further studies, however, are required to characterize any association between JAKi use and CTCL development, as well as the safety of JAKi use in the context of pre‐existing CTCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Viviane Liao, Shamir Geller
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Liao, V., Lavin, L., Ong, M. M., Pulitzer, M. P., Moskowitz, A. J., Myskowski, P. L., & Geller, S. (2025). Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17747
Vancouver
Liao V, Lavin L, Ong MM, Pulitzer MP, Moskowitz AJ, Myskowski PL, et al. Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17747
BibTeX
@article{Liao2025,
author = {Liao, Viviane and Lavin, Leore and Ong, Michael M and Pulitzer, Melissa P and Moskowitz, Alison J and Myskowski, Patricia L and Geller, Shamir},
title = {Oral and Topical Janus Kinase Inhibitors in Patients With Cutaneous T‐Cell Lymphoma: A Real‐World Single‐Center Experience},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17747}
}
EUVIMED